A Russian original medication called Polyoxidonium® by Petrovax, a pharmaceutical company affiliated to the Interros Group, has passed the first phase of an international clinical trial for its effectiveness and safety for COVID-19 treatment.

Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.

PJSC MMC Norilsk Nickel, the world's largest producer of palladium and high-grade nickel and a major producer of platinum and copper, will be the first issuer of tokens in the project and the first industrial company to tokenize its assets on the platform.